Wednesday, July 8, 2026

Drug profile · INN

pioglitazone hydrochloride

pioglitazone hydrochloride (PIOGLITAZONE HYDROCHLORIDE) is a peroxisome proliferator-activated receptor gamma agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 64
News articles 0
Drug details — pioglitazone hydrochloride
US status
approved
Class
Route
ORAL
Patents
20
Programs
64
Data quality
0.89

Quick answer

pioglitazone hydrochloride (PIOGLITAZONE HYDROCHLORIDE) is a peroxisome proliferator-activated receptor gamma agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN pioglitazone hydrochloride
Brand PIOGLITAZONE HYDROCHLORIDE
Mechanism Peroxisome proliferator-activated receptor gamma agonist
Target Peroxisome proliferator-activated receptor gamma
Route ORAL
Formulation TABLET
Originator Takeda

Mechanism of action

Peroxisome proliferator-activated receptor gamma agonist

Primary target: Peroxisome proliferator-activated receptor gamma

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. APHP230847 Phase 3 · PARItec · Pulmonary arterial hypertension
  2. Alogliptin and pioglitazone Phase 3 · Takeda · Diabetes Mellitus
  3. Alogliptin and pioglitazone Phase 3 · Takeda · Type 2 Diabetes Mellitus
  4. CADET-PAD Phase 3 · COLLEGIUM PHARMACEUTICAL · Ischemia of the lower limbs in the course of obstructive art
  5. CLI-06657AA1-03 Phase 3 · Chiesi Farmaceutici S.p.A · Fabry disease (α-galactosidase A deficiency)
  6. CT-L03-301 Phase 3 · Celltrion Healthcare Australia · Type 2 diabetes mellitus (T2DM)
  7. D20180102 Phase 3 · PARItec · Vascular calcification and type 1 diabetes
  8. Lactose Placebo Phase 3 · United Therapeutics Europe · Elbow Fracture

Related & competitor drugs

  1. rosiglitazone maleate Peroxisome proliferator-activated receptor gamma agonist
  2. troglitazone Peroxisome proliferator-activated receptor gamma agonist
  3. leriglitazone Alimentary tract and metabolism (A16)
  4. rosiglitazone Alimentary tract and metabolism (A10)
  1. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12268700

    3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11396571

    Polymers including galactose based blocks and uses thereof

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11116823

    Treatment of α-galactosidase a deficiency

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10870842

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10744154

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10280414

    Stabilized α-galactosidase and uses thereof

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10253294

    Galactose oxidase treatment of dendritic cells to improve their immunogenicity

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9796756

    Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 9732333

    Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 9708595

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 9567572

    Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9320714

    Tablet

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9249179

    Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9200090

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9194011

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9101660

    Solid preparation

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8940513

    Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof

    Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8865217

    Oral preparation comprising pioglitazone

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is pioglitazone hydrochloride?

pioglitazone hydrochloride (PIOGLITAZONE HYDROCHLORIDE) is a peroxisome proliferator-activated receptor gamma agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for pioglitazone hydrochloride?

PIOGLITAZONE HYDROCHLORIDE is a marketed brand name for pioglitazone hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pioglitazone hydrochloride?

pioglitazone hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.